Danuglipron, on the other hand, appears to achieve comparable metabolic benefits of weight loss and glycemic control in less than half the time
p = 0.0009), reflecting an 87% decrease in risk
Brian Wojeck, an obesity medicine specialist at the Yale School of Medicine, likened it to what happens after bariatric surgery, in which patients often experience temporary shedding due to stress and rapid metabolic change
Conclusion Managing DKD requires a multifaceted approach, starting with lifestyle advice, addressing the CV risk factors of hypertension and dyslipidaemia, treating hyperglycaemia, and harnessing the cardiorenal protective properties of specific drugs
If youre ready to take the next step toward sustainable weight loss, schedule a consultation to determine whether Zepbound or Wegovy is right for you